Regeneron Pharmaceuticals, Inc. (REGN)
Largest Insider Buys in Sector
REGN Stock Price History Chart
REGN Stock Performance
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection …
Insider Activity of Regeneron Pharmaceuticals, Inc.
Over the last 12 months, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $307.91M worth of Regeneron Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $2.65B worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 105,820 shares for transaction amount of $51.01M was made by Sanofi (10 percent owner) on 2017‑08‑24.
List of Insider Buy and Sell Transactions, Regeneron Pharmaceuticals, Inc.
| 2024-11-01 | Sale | EVP Commercial | 1,000 0.0009% | $844.61 | $844,610 | -1.75% | ||
| 2024-10-01 | Sale | director | 100 <0.0001% | $1,048.78 | $104,878 | -4.57% | ||
| 2024-10-01 | Sale | EVP Commercial | 1,000 0.0009% | $1,054.06 | $1.05M | -4.57% | ||
| 2024-09-03 | Sale | director | 100 <0.0001% | $1,178.68 | $117,869 | -13.03% | ||
| 2024-09-03 | Sale | EVP Commercial | 1,000 0.0009% | $1,178.73 | $1.18M | -13.03% | ||
| 2024-08-28 | Sale | SVP Finance & CFO | 5,444 0.005% | $1,205.31 | $6.56M | -13.16% | ||
| 2024-08-15 | Sale | director | 10,838 0.0103% | $1,158.17 | $12.55M | 0.00% | ||
| 2024-08-15 | Sale | director | 756 0.0007% | $1,170.00 | $884,520 | 0.00% | ||
| 2024-08-14 | Sale | EVP Research | 6,363 0.006% | $1,153.15 | $7.34M | 0.00% | ||
| 2024-08-08 | Sale | EVP Research and Development | 5,197 0.0047% | $1,084.54 | $5.64M | +1.15% | ||
| 2024-08-07 | Sale | VP Controller | 487 0.0005% | $1,070.00 | $521,090 | +4.99% | ||
| 2024-08-02 | Sale | director | 756 0.0007% | $1,115.00 | $842,940 | +1.89% | ||
| 2024-08-01 | Sale | director | 100 <0.0001% | $1,085.67 | $108,567 | -0.11% | ||
| 2024-08-01 | Sale | EVP Commercial | 1,137 0.001% | $1,060.86 | $1.21M | -0.11% | ||
| 2024-07-11 | Sale | EVP General Counsel and Secret | 1,866 0.0018% | $1,088.95 | $2.03M | 0.00% | ||
| 2024-07-01 | Sale | director | 100 <0.0001% | $1,059.24 | $105,924 | 0.00% | ||
| 2024-07-01 | Sale | EVP Commercial | 1,137 0.001% | $1,047.11 | $1.19M | 0.00% | ||
| 2024-06-24 | Sale | director | 756 0.0007% | $1,062.00 | $802,872 | +1.32% | ||
| 2024-06-14 | Sale | director | 1,535 0.0015% | $1,040.00 | $1.6M | +3.34% | ||
| 2024-06-12 | Sale | Bd. Co-Chair, President & CEO | 16,149 0.015% | $1,015.94 | $16.41M | +4.09% |
Insider Historical Profitability
| SING GEORGE L | director | 26349 0.0243% | $814.56 | 2 | 49 | +19.37% |
| RYAN ARTHUR F | director | 17582 0.0162% | $814.56 | 1 | 60 | +15.03% |
| POON CHRISTINE A | director | 2172 0.002% | $814.56 | 2 | 6 | +28.16% |
| Sanofi | 10 percent owner | 279766 0.258% | $814.56 | 53 | 7 | +15.98% |
Institutional Investor Ownership
| Fidelity Investments | $10.39B | 9.8 | 10.79M | +4.62% | +$458.78M | 0.7 | |
| The Vanguard Group | $8.6B | 8.11 | 8.93M | +1.04% | +$88.51M | 0.16 | |
| BlackRock | $8.25B | 7.78 | 8.57M | -0.71% | -$58.76M | 0.18 | |
| JPMorgan Chase | $7.44B | 7.01 | 7.73M | +6.92% | +$481.63M | 0.66 | |
| State Street | $4.66B | 4.39 | 4.84M | -1.22% | -$57.46M | 0.19 |